CE: Improving Treatment Regimens in Pulmonary Arterial Hypertension: The Health-System Pharmacist’s Role

Pharmacy Times Health Systems Edition, July 2020, Volume 9, Issue 4

Pulmonary arterial hypertension is an uncommon disease characterized by smooth muscle and endothelial cell proliferation and progressive vasoconstriction of the small pulmonary arteries.

THIS ACTIVITY IS SUPPORTED BY ACTELION PHARMACEUTICALS US, INC.THIS ACTIVITY IS JOINTLY SPONSORED BY RUTGERS BIOMEDICAL AND HEALTH SCIENCES, ERNEST MARIO SCHOOL OF PHARMACY

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Explain the pathophysiology of pulmonary arterial hypertension (PAH), the World Health Organization classifications, and genetic contributors to disease severity
  • Examine clinical evidence involving the use of dual and triple regimens in PAH management
  • Explore the clinical efficacy, safety, dosing and administration of current and emerging PAH therapies
  • Identify opportunities for health-system pharmacists to intervene in PAH care to improve patient outcomes

FACULTY

Rebecca L. Attridge, PharmD, MSc, BCPS

Professor, University of the Incarnate Word Feik School of Pharmacy, Department of Pharmacy Practice

Adjunct Assistant Professor, UT Health, Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine, San Antonio, Texas

Rebecca D. Moote, PharmD, MSc, BCPS

Clinical Associate Professor, The University of Texas College of Pharmacy, Division of Pharmacotherapy, UT Health San Antonio, San Antonio, Texas

Adjunct Associate Professor, UT Health San Antonio, Department of Medicine, San Antonio, Texas

TARGET AUDIENCE: Health-system pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: June 29, 2020

EXPIRATION DATE: July 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.